medigraphic.com
ISSN 0016-3813 (Print)

2013, Number 6

<< Back Next >>

Gac Med Mex 2013; 149 (6)

Neuroendocrine differentiation in prostate adenocarcinome

Ramírez-Balderrama L, López-Briones S, Daza-Benítez L, Macías MH, López-Gaytán T, Pérez-Vázquez V

Language: Spanish
References: 50
Page: 639-645
PDF size: 222.60 Kb.


ABSTRACT

The human prostate is a gland composed of many types of cells and extracellular components with specific functions. The stromal compartment includes nerve tissue, fibroblasts, lymphocytes, macrophages, endothelial cells, and smooth muscular cells. The epithelial compartment is composed of luminal epithelial cells, basal cells, and a lesser number of neuroendocrine cells, which are transcendental in growth regulation, differentiation, and secretory function. In prostate cancer, neuroendocrine cells replicate especially in high grade and advanced stage, and hormonally treated tumoral cells adopt characteristics that make them resistant to hormonal deprivation. Androgen receptors have a crucial role in tumorigenesis of prostate adenocarcinoma. Deprivation hormone therapy blocks the expression of androgen receptors in the prostatic epithelial cells. Neuroendocrine cells lack androgen receptors; their growth is hormonally independent and that is why deprivation hormonal therapy does not eliminate the neoplasic neuroendocrine cells. In contrast, these types of cells proliferate after therapy and make a paracrine network, stimulating the proliferation of androgen-independent neoplastic cells, which finally lead to tumoral recurrence. In this work we describe the neuroendocrine function in normal tissue and in prostatic adenocarcinoma, including neoplasic proliferation stimulation, invasion, apoptosis resistance, and angiogenesis, and describe some molecular pathways involved in this neuroendocrine differentiation.


REFERENCES

  1. Aumüller G. Morphologic and endocrine aspects of prostatic function. Prostate. 1983;4:195-214.

  2. Bonkhoff H, Remberger K. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch Pathol Anat Histopathol. 1993;422:35-8.

  3. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. Am J Transl Res. 2009;1:148-62.

  4. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol. 1995;26:167-70.

  5. Komiya A, Suzuki H, Imamoto T, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 2009;16(1):37-44.

  6. Huss WJ, Gray DR, Werdin ES, Funkhouser WK, Smith GJ. Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model. Prostate. 2004;160:77-90.

  7. Aumüller G, Leonhardt M, Janssen M, Konrad L, Bjartell A, Abrahamsson PA. Neurogenic origin of human prostate endocrine cells. Urology. 1999; 53:1041-8.

  8. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjřlnerřd OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate. 1997;30:1-6.

  9. Kamiya N, Akakura K, Suzuki H, et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol. 2003;44:309-14.

  10. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;167:512-5.

  11. Sasaki T, Komiya A, Suzuki H, et al. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol. 2005;48:224-9.

  12. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl. 1998;8:43-51.

  13. Iwamura M, Koshiba K, Cockett AT. Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate Suppl. 1998;8:14-7.

  14. Dasilva JO, Amorino GP, Casarez EV, Pemberton B, Parsons SJ. Neuroendocrine- derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling. Prostate. 2013;73(8):801-12.

  15. Diaz M, Abdul M, Hoosein N. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl. 1998;8: 32-6.

  16. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate. 2000;42:186-95.

  17. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrineparacrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 1991;19:91-8.

  18. Sciarra A, Mariotti G, Gentile V, et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int. 2003;91: 438-45.

  19. Tarján M. Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death. Indian J Urol. 2010;26:41-5.

  20. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47: 147-55.

  21. Huang J, Yao JL, di Sant’Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate. 2006;66:1399-406.

  22. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57:205-25.

  23. Shah RB, Tadros Y, Brummell B, Zhou M. The diagnostic use of ERG in resolving an «atypical glands suspicious for cancer» diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoAracemase markers. Hum Pathol. 2013 May;44(5):786-94.

  24. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001;48:7-15.

  25. Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461:495-500.

  26. Cheville JC, Tindall D, Boelter C, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2012;95:1028-36.

  27. Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83:1-11.

  28. Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol. 1994;18:1240-6.

  29. Puccetti L, Supuran CT, Fasolo PP, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol. 2005;48:215-21.

  30. Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005;66:386-91.

  31. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjřlnerřd OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate. 1997;31:110-7.

  32. Lilleby W, Paus E, Skovlund E, Fossĺ SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate. 2001;46:126-33.

  33. Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 2004;64:5489-95.

  34. Uchida K, Masumori N, Takahashi A, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate. 2006;66:536-45.

  35. Xiao D, Qu X, Weber HC. GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept. 2002;109:141-8.

  36. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009;69:151-60.

  37. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289-96.

  38. Nagakawa O, Murakami K, Yamaura T, et al. Expression of membranetype 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett. 2000;155:173-9.

  39. Vanoverberghe K, Vanden Abeele F, Mariot P, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 2004;11:321-30.

  40. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate. 2002;53:50-9.

  41. Mazzucchelli R, Scarpelli M, Lopez-Beltran A, et al. Immunohistochemical expression and localization of somatostatin receptors in normal prostate, high grade prostatic intraepithelial neoplasia and prostate cancer and its many faces. J Biol Regul Homeost Agents. 2012;26:181-92.

  42. Vainas G, Pasaitou V, Galaktidou G, et al. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res. 1997;16:119-26.

  43. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab. 2001;86:5729-36.

  44. Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res. 2004;10:4398-405.

  45. Verhelst J, De Longueville M, Ongena P, Denis L, Mahler C. Octreotide in advanced prostatic cancer relapsing under hormonal treatment. Acta Urol Belg. 1994;62:83-8.

  46. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295-303.

  47. Hansson J, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl. 2003;212:28-36.

  48. Levine L, Lucci JA, Pazdrak B, et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 2003;63:3495-502.

  49. Dizeyi N, Bjartell A, Hedlund P, Taskén KA, Gadaleanu V, Abrahamsson PA. Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol. 2005;47:895-900.

  50. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005;65:2825-31.




2020     |     www.medigraphic.com